Ulcerative colitis Medical Services in China

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease (IBD) characterized by diffuse mucosal inflammation and ulceration limited to the colon and rectum. Unlike Crohn’s disease, UC never involves the small intestine and does not exhibit transmural inflammation or skip lesions. The disease typically begins in the rectum and extends proximally in a continuous pattern. Pathogenesis involves a dysregulated immune response to gut microbiota in genetically susceptible individuals—key susceptibility loci include genes within the HLA region, IL23R, and ECM1. Environmental triggers such as antibiotic exposure in early life, Western diet (high in fat and refined sugars), smoking cessation (paradoxically protective in UC vs. harmful in Crohn’s), and urban living contribute to loss of mucosal barrier integrity and aberrant T-cell activation, particularly Th2 and innate lymphoid cell type 2 (ILC2) responses. Epidemiologically, UC has a bimodal incidence peak: first in adolescence/early adulthood (ages 15–30) and second in older adults (ages 50–70). Prevalence in high-income countries ranges from 100 to 200 per 100,000 persons; in China, incidence has risen sharply over the past two decades, now estimated at 1.5–3.0 per 100,000 annually, reflecting rapid urbanization and dietary shifts. Key risk factors include family history (first-degree relative increases risk 4–10 fold), nonsteroidal anti-inflammatory drug (NSAID) use, appendectomy (protective if performed before age 20), and vitamin D deficiency. UC significantly impairs quality of life: patients report fatigue, fecal urgency/incontinence, abdominal pain, and social withdrawal—up to 40% experience clinically significant anxiety or depression. Work absenteeism averages 12–18 days/year during active flares, and long-term complications—including primary sclerosing cholangitis, colorectal dysplasia (risk rises after 8–10 years of disease), and increased colorectal cancer risk—further erode functional status. Nutritional deficiencies (iron, vitamin B12, folate, vitamin D) are common due to chronic blood loss and malabsorption. Early diagnosis via colonoscopy with biopsy, calprotectin testing, and serologic markers (e.g., ASCA-negative/pANCA-positive profile) is critical to guide therapy and prevent irreversible structural damage.

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease (IBD) characterized by diffuse mucosal inflammation and ulceration limited to the colon and rectum. Unlike Crohn’s disease, UC does not involve transmural inflammation or skip lesions, and its anatomical extent is continuous—from the rectum proximally, with variable involvement of the left colon (proctosigmoiditis), distal colon (left-sided colitis), or entire colon (pancolitis). The precise etiology remains incompletely understood; however, current evidence supports a multifactorial pathogenesis involving dysregulated immune responses to luminal antigens in genetically susceptible individuals, modulated by environmental exposures.

Genetic factors play a substantial role in UC susceptibility. Genome-wide association studies (GWAS) have identified over 200 risk loci associated with IBD, many shared between UC and Crohn’s disease, though some exhibit UC-specific enrichment. Notable genes include *IL23R*, *IL10*, *IL10RA*, *IL10RB*, and *HNF4A*, implicating pathways involved in epithelial barrier integrity, interleukin-10–mediated anti-inflammatory signaling, and Th17 cell differentiation. First-degree relatives of UC patients carry a 10- to 15-fold increased risk, and monozygotic twin concordance rates range from 10% to 15%, underscoring that genetics alone are insufficient to cause disease—environmental co-factors are essential.

Environmental triggers and modifiers significantly influence disease onset, activity, and course. Cigarette smoking exerts a paradoxical protective effect in UC (unlike its detrimental role in Crohn’s disease); former smokers have higher incidence and more severe disease than never-smokers, while active smoking correlates with reduced risk and milder phenotypes—likely via nicotine-mediated modulation of mucosal immunity and epithelial restitution. Dietary patterns also contribute: high intake of refined sugars, omega-6 fatty acids, and processed foods may promote dysbiosis and pro-inflammatory signaling, whereas diets rich in fiber, fruits, vegetables, and omega-3 fatty acids appear modestly protective. Antibiotic exposure—particularly in childhood—is associated with increased UC risk, likely through disruption of early-life microbiota colonization and immune education. Appendectomy before age 20 confers a ~60% reduction in UC risk, suggesting a potential immunomodulatory role of the appendix in gut-associated lymphoid tissue development.

The intestinal microbiome is central to UC pathogenesis. Patients consistently demonstrate microbial dysbiosis, including reduced diversity, depletion of commensal Firmicutes (e.g., *Faecalibacterium prausnitzii*, a butyrate-producing anti-inflammatory species), and expansion of potentially pro-inflammatory Proteobacteria (e.g., adherent-invasive *Escherichia coli* strains). This dysbiosis may impair short-chain fatty acid (SCFA) production—particularly butyrate—which serves as the primary energy source for colonic epithelial cells and maintains regulatory T-cell function and mucosal homeostasis.

Other established risk factors include age (peak incidence in the second and third decades, with a second smaller peak in the sixth to seventh decades), ethnicity (higher prevalence among Ashkenazi Jewish populations), and urban residence—suggesting roles for hygiene, pollution, and lifestyle-related factors. Nonsteroidal anti-inflammatory drugs (NSAIDs) do not cause UC but can exacerbate active disease by impairing mucosal defense and promoting neutrophil infiltration. Psychological stress does not initiate UC but is a well-documented trigger of clinical flares, likely via brain-gut axis–mediated alterations in gut permeability, motility, and immune activation. Vitamin D deficiency is both a consequence of chronic inflammation and malabsorption (especially in extensive colitis) and an independent risk factor for disease severity and hospitalization.

In summary, UC arises from a complex interplay among inherited genetic variants affecting immune regulation and epithelial barrier function, environmental exposures that perturb host-microbe interactions (e.g., antibiotics, diet, smoking), and stochastic or immune-mediated events that breach mucosal tolerance. No single cause predominates; rather, disease manifests when cumulative genetic risk intersects with permissive environmental conditions during critical windows of immune development or homeostatic challenge.

Ulcerative colitis (UC) is a chronic, relapsing-remitting inflammatory bowel disease (IBD) characterized by continuous, superficial mucosal inflammation limited to the colon and rectum. It predominantly affects individuals aged 15–30 years and a second peak occurs between 50–70 years. As a condition managed primarily within gastroenterology (Digestive Medicine), UC presents with a spectrum of symptoms that evolve from early, often subtle manifestations to classic, florid features during active disease flares.

Early symptoms are frequently nonspecific and may be overlooked or misattributed to infectious gastroenteritis, irritable bowel syndrome (IBS), or medication side effects. Patients commonly report insidious onset of mild, intermittent left-sided abdominal discomfort or cramping, often exacerbated by meals. Low-grade, persistent urgency—particularly upon waking or after eating—is an underrecognized early sign. A gradual increase in stool frequency (e.g., from 1–2 to 4–5 bowel movements daily), accompanied by a subjective sense of incomplete evacuation (tenesmus), may precede overt bleeding by weeks to months. Mild fatigue, low-grade fever (<38.0°C), and subtle weight loss (≤5% body weight over 3–6 months) may also occur without overt gastrointestinal hemorrhage. Notably, up to 15% of patients present with isolated proctitis—rectal bleeding without diarrhea—making early recognition challenging in primary care settings.

Typical symptoms reflect established mucosal ulceration and acute inflammation. The hallmark triad consists of: (1) bloody diarrhea—often with visible bright-red blood mixed with stool or as frank clots; (2) frequent, urgent, and often painful defecation—patients may experience ≥6–10 stools per day during moderate-to-severe flares; and (3) tenesmus—persistent sensation of rectal fullness and straining despite minimal or no stool passage. Abdominal pain is typically crampy, localized to the left lower quadrant or diffuse, and relieved partially by defecation. Fever becomes more prominent in moderate-to-severe disease (≥38.5°C), reflecting systemic inflammatory burden. Nocturnal diarrhea is a red-flag symptom indicating significant disease activity and correlates strongly with endoscopic severity.

Accompanying (extraintestinal) manifestations occur in ~30–40% of patients and may precede, coincide with, or follow intestinal symptoms. Musculoskeletal involvement includes peripheral arthropathy (asymmetric, non-erosive, migratory joint pain affecting knees, ankles, wrists), axial spondyloarthritis (HLA-B27–associated sacroiliitis), and ankylosing spondylitis. Dermatologic manifestations include erythema nodosum (tender, subcutaneous nodules on shins, associated with disease activity) and pyoderma gangrenosum (painful, progressive ulcers with undermined borders, often refractory to therapy). Ocular complications include anterior uveitis (acute, painful, photophobic) and episcleritis (mild conjunctival injection without vision loss). Hepatobiliary associations include primary sclerosing cholangitis (PSC)—a progressive fibro-obliterative cholangiopathy strongly linked to UC (up to 75% of PSC patients have underlying IBD, most commonly UC)—and autoimmune hepatitis. Other associations include aphthous stomatitis, thromboembolic events (due to hypercoagulability), and iron-deficiency anemia secondary to chronic blood loss and impaired absorption.

Complications arise from uncontrolled inflammation, chronicity, or therapeutic interventions. Acute severe colitis (ASC), defined by ≥6 bloody stools/day plus at least one systemic marker (fever >37.8°C, tachycardia >90 bpm, anemia [Hb <10.5 g/dL], or elevated ESR/CRP), carries high risk of toxic megacolon—a life-threatening dilation (>6 cm on abdominal radiograph) with systemic toxicity, perforation, and sepsis. Chronic complications include colorectal dysplasia and carcinoma—risk increases with disease duration (1–2% at 10 years, 7–10% at 20 years, 12–20% at 30 years), extent (pancolitis confers highest risk), and concurrent PSC. Strictures—though rare in UC due to its superficial nature—may develop in long-standing disease and require differentiation from malignancy. Other complications include fulminant colitis with perforation, massive hemorrhage requiring transfusion or colectomy, and malnutrition-related sequelae (hypoalbuminemia, vitamin D/B12 deficiency, osteopenia).

Diagnosis relies on integration of clinical, endoscopic, histopathologic, and laboratory data. Colonoscopy with ileoscopy is the gold standard: findings include continuous, diffuse mucosal erythema, friability, erosions, ulcerations, loss of vascular pattern, and spontaneous bleeding—typically extending proximally from the rectum without skip lesions. Biopsies demonstrate crypt architectural distortion, basal plasmacytosis, crypt abscesses, and surface epithelial damage—features distinguishing UC from Crohn’s disease and infectious colitis. Laboratory evaluation includes CBC (microcytic anemia, leukocytosis, thrombocytosis), CRP and ESR (elevated in active disease), albumin (hypoalbuminemia reflects severity), and stool studies (C. difficile toxin PCR, culture, ova & parasite testing, calprotectin/lactoferrin—fecal biomarkers >250 µg/g strongly support IBD over IBS). Serologic markers (pANCA positivity in ~60–70% of UC vs. ASCA positivity in Crohn’s) aid classification but lack diagnostic specificity. Cross-sectional imaging (CT/MRI enterography) is not routinely indicated for diagnosis but helps exclude Crohn’s disease or assess complications like abscess or fistula (rare in UC).

Differential diagnosis is critical given overlapping presentations. Infectious colitis (e.g., Campylobacter, Shigella, Salmonella, C. difficile, CMV in immunocompromised hosts) must be excluded first—stool cultures and molecular assays are mandatory. Ischemic colitis typically presents acutely in older adults with cardiovascular risk factors, often with segmental distribution and self-limited course. Microscopic colitis (lymphocytic/collagenous) manifests with chronic watery diarrhea without blood or systemic symptoms, normal colonoscopy, and characteristic histology. Behçet’s disease may mimic UC with oral/genital ulcers and intestinal ulcers but shows discontinuous, deep, aphthoid lesions. Diversion colitis—occurring in inactive colonic segments after surgical diversion—presents with mucosal inflammation and bleeding but resolves spontaneously post-reanastomosis. Radiation proctocolitis follows pelvic radiotherapy and exhibits telangiectasias, atrophy, and fibrosis on biopsy. Finally, NSAID-induced colopathy and allergic colitis (in infants) must be considered contextually. Accurate distinction guides appropriate therapy—avoiding immunosuppression in infection or ischemia—and informs prognosis and surveillance strategies.

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by diffuse mucosal inflammation limited to the colon and rectum. Management aims to induce and maintain remission, prevent complications, minimize corticosteroid exposure, and improve quality of life. Treatment strategies are stratified according to disease extent (proctitis, left-sided, or extensive), severity (mild, moderate, or severe), and treatment response history.

Conservative treatment forms the cornerstone of UC management and must be integrated throughout the disease course. Patients are advised to adopt a low-residue, lactose-restricted diet during active flares to reduce mechanical irritation and diarrhea; however, no universal 'UC diet' is evidence-based for long-term maintenance. Nutritional assessment is essential—up to 85% of hospitalized patients exhibit malnutrition, particularly deficiencies in iron, vitamin D, folate, and vitamin B12 due to chronic blood loss, malabsorption, and reduced intake. Enteral nutrition is not routinely recommended for induction in adults (unlike Crohn’s disease), but oral nutritional supplements may support recovery in undernourished individuals. Smoking cessation is strongly encouraged, as tobacco use paradoxically correlates with lower UC incidence and milder disease—but this does not justify smoking due to overwhelming systemic health risks. Stress reduction techniques—including cognitive behavioral therapy and mindfulness-based interventions—are adjunctive tools shown to modestly improve symptom perception and reduce flare frequency, though they do not alter objective inflammatory markers.

Pharmacotherapy is tailored to disease activity and location. For mild-to-moderate distal disease (proctitis or proctosigmoiditis), topical 5-aminosalicylates (5-ASAs)—such as mesalamine enemas (4 g nightly) or suppositories (1 g daily)—achieve remission in >70% of cases with minimal systemic absorption. Oral 5-ASAs (mesalamine, sulfasalazine, olsalazine, balsalazide) remain first-line for mild-to-moderate extensive UC; dosing is weight-based (e.g., mesalamine 2.4–4.8 g/day), with efficacy dependent on adequate adherence and colonic release formulation. Corticosteroids (e.g., prednisone 40–60 mg/day orally or budesonide MMX 9 mg/day) are reserved for moderate-to-severe flares to induce remission—not for maintenance—due to unacceptable long-term toxicity (osteoporosis, diabetes, cataracts, adrenal suppression). In steroid-refractory or steroid-dependent cases, immunomodulators—including thiopurines (azathioprine 2–3 mg/kg/day or 6-mercaptopurine 1–1.5 mg/kg/day) and methotrexate (15–25 mg/week SC)—are used for steroid-sparing maintenance, requiring therapeutic drug monitoring and vigilant surveillance for myelosuppression and infection. Biologic therapies have revolutionized UC care: anti-tumor necrosis factor agents (infliximab, adalimumab, golimumab) are effective for moderate-to-severe UC unresponsive to conventional therapy; vedolizumab (an α4β7 integrin inhibitor) offers gut-selective action with favorable safety; and ustekinumab (anti-IL-12/23) and newer agents like mirikizumab (anti-IL-23p19) and tofacitinib (a JAK1 inhibitor) provide additional mechanistic options. Therapeutic drug monitoring (TDM) of biologics—measuring trough levels and anti-drug antibodies—is increasingly standard to optimize dosing and prevent secondary loss of response.

Surgical treatment is definitive and curative for UC, indicated in cases of acute severe colitis unresponsive to intravenous corticosteroids and rescue therapy (e.g., infliximab or cyclosporine), dysplasia or colorectal cancer, chronic refractory disease impairing growth or development (in pediatric patients), or life-threatening complications including toxic megacolon, perforation, or massive hemorrhage. The gold-standard procedure is total proctocolectomy with ileal pouch-anal anastomosis (IPAA), preserving continence while eliminating disease. Laparoscopic and robotic-assisted approaches are now routine in high-volume centers, reducing postoperative pain, length of stay, and wound complications. Alternative options include total colectomy with end ileostomy for high-risk or elderly patients, or continent ileostomy (Kock pouch) in select cases. Surgery eliminates colorectal cancer risk and obviates lifelong medical therapy, though pouch-related complications (e.g., pouchitis, strictures, fistulae) occur in ~50% over 10 years and require ongoing gastroenterological follow-up.

China offers distinct advantages in UC management, anchored in its integrated healthcare infrastructure and rapidly evolving clinical ecosystem. First, China hosts some of the world’s largest IBD specialty centers—such as Peking Union Medical College Hospital and Ruijin Hospital—where multidisciplinary teams (gastroenterologists, colorectal surgeons, nutritionists, pathologists, and endoscopists) collaborate within unified electronic health records, enabling seamless longitudinal care. Second, China has pioneered cost-effective biosimilar adoption: multiple high-quality infliximab, adalimumab, and vedolizumab biosimilars are approved and reimbursed under the National Reimbursement Drug List (NRDL), reducing biologic therapy costs by up to 60% compared with originators—dramatically improving access. Third, China leads in real-world evidence generation through national IBD registries (e.g., the China IBD Cohort Study), which inform local treatment guidelines reflecting regional epidemiology, microbiome profiles, and pharmacogenomic variations (e.g., higher TPMT variant prevalence influencing thiopurine dosing). Fourth, advanced endoscopic capabilities—including high-definition chromoendoscopy, narrow-band imaging, and AI-assisted dysplasia detection—are widely deployed, enhancing surveillance accuracy. Finally, traditional Chinese medicine (TCM) is integrated judiciously: certain herbal formulations (e.g., Weichang’an) demonstrate adjunctive efficacy in randomized trials for mild-moderate UC when combined with mesalamine, though TCM is never used monotherapy for moderate-severe disease or as replacement for evidence-based biologics or surgery.

Recovery and long-term management emphasize proactive partnership between patient and provider. Patients should undergo annual colonoscopic surveillance starting 8 years after diagnosis for pancolitis or 12–15 years for left-sided disease, with targeted biopsies per SCENIC guidelines. Vaccination status must be optimized pre-immunosuppression (e.g., pneumococcal, influenza, hepatitis B, varicella-zoster); live vaccines are contraindicated during biologic or thiopurine therapy. Bone mineral density screening is recommended every 2–5 years in patients receiving cumulative corticosteroids ≥3 months. Mental health screening for depression and anxiety is integral, given their high prevalence and bidirectional relationship with disease activity. Patients are educated on symptom diaries, early warning signs of flare (e.g., >4 bloody stools/day, nocturnal diarrhea, fever), and prompt escalation pathways. Pregnancy counseling is essential: most UC medications—including 5-ASAs, biologics, and thiopurines—are considered safe during conception and gestation, supporting planned, well-controlled pregnancies. With comprehensive, individualized, and timely intervention, over 90% of UC patients achieve sustained clinical remission, preserve intestinal function, and lead full, productive lives.